CALGARY, Alberta--(BUSINESS WIRE)--Feb. 25, 2004--Cellway Ventures Inc. (OTCBB:CWYV - News), a Calgary-based company commencing operations in the biotechnology, pharmaceutical and diagnostics industries, today announced that it is in advanced negotiations with a group of European scientists to purchase the patents and all associated rights to their highly predictive, metastic cancer molecular diagnostic test products.
The diagnostic test products have been commercialized and are ready for market introduction.
Cellway Ventures will release further information as it becomes available.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB and our subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
Contact:
Cellway Ventures Inc. Scott Lawler, 403-693-8014
Source: Cellway Ventures Inc.